Investment analysts at StockNews.com initiated coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Regulus Therapeutics in a report on Monday, May 9th.
Regulus Therapeutics stock opened at $0.28 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 12.32 and a current ratio of 12.32. Regulus Therapeutics has a 52-week low of $0.16 and a 52-week high of $1.05. The firm has a 50 day moving average price of $0.24 and a two-hundred day moving average price of $0.27. The firm has a market cap of $41.46 million, a price-to-earnings ratio of -0.95 and a beta of 2.18.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp boosted its stake in Regulus Therapeutics by 42.9% in the first quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 50,518 shares in the last quarter. Morgan Stanley boosted its stake in shares of Regulus Therapeutics by 13.0% during the third quarter. Morgan Stanley now owns 564,462 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 64,837 shares during the period. Geode Capital Management LLC raised its holdings in shares of Regulus Therapeutics by 13.8% during the third quarter. Geode Capital Management LLC now owns 670,747 shares of the biopharmaceutical company’s stock valued at $463,000 after acquiring an additional 81,551 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Regulus Therapeutics by 498.2% during the first quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 111,100 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Regulus Therapeutics by 21.4% during the first quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after acquiring an additional 648,121 shares in the last quarter. 47.06% of the stock is owned by institutional investors.
Regulus Therapeutics Company Profile (Get Rating)
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.
- Get a free copy of the StockNews.com research report on Regulus Therapeutics (RGLS)
- ABM Industries, A Clean Play For Dirty Economic Times
- Should Silver Stocks Be A Part Of Your Portfolio?
- This Still Isn’t A Buyable Bottom For Stocks
- Don’t Get Too Bullish On Lennar Even Though It’s A Good Buy
- Two Defensive Stocks To Get Aggressive With
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.